Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2019-02-20
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of bendamustine hydrochloride
when given together with gemcitabine hydrochloride and to see how well it works in treating
patients with relapsed or refractory Hodgkin lymphoma. Drugs used in chemotherapy, such as
gemcitabine hydrochloride and bendamustine hydrochloride, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving
more than one drug, combination chemotherapy, may kill more cancer cells.